MarginsXMarginsX
Home › Markets › Health Care › JUNS

Jupiter Neurosciences Inc. (JUNS)

JUNS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.70
-8.11% on the day
Market cap
$2.2M
Nano cap
Revenue · 2025
$22K
Prior year not contiguous
Net income · 2025
-$8.6M
-39662.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1679628/000149315226014687/0001493152-26-014687-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerJUNS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2024
SEC CIK0001679628
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$22K
Net income-$8.6M
Operating income-$8.9M
Net margin-39662.8%
Operating margin-40873.2%
Revenue growthNo prior-year revenue to compare
Cash$3.8M
Total assets$5.6M
P/E (computed)Net income was not positive
P/S (computed)102.8×

Warning signs

Cash runway
2.5 months
$1.5M cash at June 30, 2026
Share count, 1 year
+65.8%
2025-08-18 to 2026-08-14
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Our management has concluded that factors raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report;"
10-Q 2026-08-14
Cash and burn$1.5M cash; operating cash flow -$1.8M a quarter.Report 2026-06-30
Shares outstanding770,081 (2026-08-14); 34,833,083 a year earlier. 1y figure adjusted for split (1-for-75 overall).Cover page 2026-08-14
Reverse splits, 3 years1; latest 1-for-75 on 2026-08-07Source 2026-08-07
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-08-24
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-08-28
AuditorCherry Bekaert LLP, Tampa, Florida, United States; changed auditors 1 time in 24 months8-K 4.01 2025-04-21
Late filings, 12 months1 NT noticeNT 10-K 2026-04-01
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30
Market cap checkThe listing's market cap implies 1,318,521 shares at the 2026-11-13 price; the latest SEC cover count is 770,081 as of 2026-08-14. One of the two share counts is stale.Nasdaq screener and SEC cover page

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$24K-$2.3M-$2.3M$1.5M$4.3MNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
$19K-$2.1M-$1.4M$2.4M$10.4MNeeds four quarters10-Q 2026-05-14
Q4 2025
2025-12-31
Not filed-$2.6M-$2.4M$3.8M$11.3M$22K10-K 2026-04-01
Q3 2025
2025-09-30
Not filed-$2.3M-$1.2M$724KNo debt tagsNeeds four quarters10-Q 2025-11-14
Q2 2025
2025-06-30
Not filed-$2.3M-$828K$1.9MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
$0-$1.5M-$1.1M$2.7MNo debt tagsNeeds four quarters10-Q 2026-05-14
Q4 2024
2024-12-31
Not filed-$1.5M-$3.7M$3.8MNo debt tags$010-K 2026-04-01
Q3 2024
2024-09-30
Not filed-$591K-$43K$253$528KNeeds four quarters10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-09-25
Latest annual report10-K2026-04-01
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-09-03
Latest proxyDEF 14A2026-06-22

Source: SEC EDGAR submissions feed, 204 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-20.0%
1 month-47.6%
3 months-70.7%
Year to date-97.7%
1 year-98.2%
From 52-week high-98.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
DCOYDecoy Therapeutics Inc.$0.9010-7.61%$2.1M
SBFMSunshine Biopharma Inc.$2.60-3.70%$2.1M
CMNDClearmind Medicine Inc. Common Shares$4.18-7.67%$2.1M
PRFXPRF Technologies Ltd.$0.6948-11.22%$2.4M
PPCBPropanc Biopharma Inc.$1.89-2.62%$2.0M
GNPXGenprex Inc.$1.90-8.65%$2.5M
ONCOOnconetix Inc.$2.91-9.35%$1.9M
REVBRevelation Biosciences Inc.$3.82-10.43%$2.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier